Cabotegravir/Rilpivirine Injections Preferred for HIV Treatment: CROI 2026 Data

The long-acting injectable combination of cabotegravir and rilpivirine (CAB+RPV LA) is demonstrating increasing versatility in HIV treatment, with new data suggesting a strong preference among patients starting treatment for the first time. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, research indicates that individuals new to HIV therapy often favor the convenience of these injections over daily oral medication. This preference, coupled with ongoing studies evaluating efficacy across varying viral loads, positions CAB+RPV LA as a potentially significant shift in HIV care.

Expanding Treatment Options

Traditionally, HIV treatment has relied heavily on daily oral regimens. Whereas, CAB+RPV LA, marketed as Cabenuva by ViiV Healthcare, offers an alternative administration schedule – either monthly or every two months – which can significantly improve adherence and quality of life for patients. The appeal extends beyond simply reducing pill burden; the recent data presented at CROI 2026 highlights a clear patient preference for the injectable format. ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, reported that in a study of adolescents aged 12 to under 18, 94.4% maintained viral suppression at week 96 after switching to CAB+RPV LA, and over 97% expressed a preference for injections over daily pills. ViiV Healthcare’s press release details these findings.

VOLITION and OPERA Studies: Deeper Insights

The presentations at CROI 2026 focused on two key studies: VOLITION and OPERA. The VOLITION study specifically assessed the preferences of treatment-naive patients – those newly diagnosed with HIV and starting therapy – comparing CAB+RPV LA to standard daily oral pills. The results, as reported by AJMC, demonstrate a notable inclination towards the injectable option. The OPERA study, meanwhile, investigated the effectiveness of CAB+RPV LA in patients with differing viral load levels – those with 50 copies/mL or more versus those with less than 50 copies/mL – providing a more nuanced understanding of the treatment’s performance across a broader patient spectrum.

The Financial Implications for ViiV Healthcare

The success of Cabenuva is a significant driver for ViiV Healthcare. While specific revenue figures for the drug were not immediately available, the expanding indications and positive patient feedback suggest potential for substantial growth. The company’s commitment to long-acting treatments is evident in its ongoing research and development efforts, as demonstrated by the presentation of additional pediatric data at CROI 2026, including the IMPAACT 2036 (CRAYON) study, which provided pharmacokinetic and safety data on CAB+RPV LA in children as young as two years traditional. NATAP reports on this pediatric research.

Impact on the HIV Treatment Landscape

The introduction of long-acting injectables like CAB+RPV LA represents a paradigm shift in HIV management. For decades, daily oral medication has been the standard of care, requiring consistent adherence for optimal viral suppression. Non-adherence can lead to viral rebound, drug resistance, and poorer health outcomes. By reducing the frequency of administration and offering a more convenient option, CAB+RPV LA aims to address this critical challenge. This represents particularly essential for populations facing barriers to consistent medication access or those who struggle with daily pill regimens.

Adolescent Treatment and the MOCHA Study

The IMPAACT 2017 (MOCHA) study, with week 96 results presented at CROI 2026, focused specifically on adolescents living with HIV. This demographic often faces unique challenges in adhering to treatment protocols. The MOCHA study’s findings – 94.4% viral suppression at week 96 among adolescents who switched to CAB+RPV LA – are particularly encouraging, suggesting that the injectable regimen can be highly effective in this population. This builds on prior research, and demonstrates the potential for improved outcomes among young people living with HIV.

Regulatory and Market Considerations

CAB+RPV LA has already been approved for maintenance of viral suppression in adults and adolescents ≥35 kg with HIV-1 infection, as noted in the IMPAACT 2036 (CRAYON) study background. The IMPAACT Network provides details on the study’s objectives. The ongoing research, including the studies presented at CROI 2026, will likely inform future regulatory decisions regarding expanded indications, such as use in treatment-naive patients and younger children. Market competition in the HIV treatment space remains intense, with several pharmaceutical companies developing and marketing various antiretroviral therapies. However, the unique advantages of CAB+RPV LA – convenience, patient preference, and demonstrated efficacy – position it as a strong contender in this evolving landscape.

Potential Challenges and Risks

While the data surrounding CAB+RPV LA are promising, several challenges and risks remain. Injection-site reactions are a potential side effect, although generally mild to moderate. The cost of the treatment may also be a barrier to access for some patients, particularly in resource-limited settings. Long-term data on the durability of viral suppression and the emergence of drug resistance are still being collected. Continued monitoring and research will be crucial to address these concerns and ensure the long-term success of CAB+RPV LA.

Looking Ahead: Pediatric Expansion and Ongoing Research

The presentation of data from the CRAYON study at CROI 2026, focusing on children as young as two years old, signals a significant step towards expanding access to CAB+RPV LA to younger populations. Further research will be needed to optimize dosing regimens and assess long-term safety and efficacy in this vulnerable group. Ongoing studies are exploring the potential of CAB+RPV LA in combination with other antiretroviral agents, aiming to further enhance treatment outcomes and address the evolving needs of individuals living with HIV. The continued evaluation of patient preferences, coupled with rigorous clinical trials, will be essential to shaping the future of HIV treatment and improving the lives of those affected by this chronic condition.